Asia
Innogen Pharma Gets Clinical Trial Nod for Obesity Drug in China
Guangzhou Innogen Pharmaceutical (HKG:2591) obtained approval to conduct phase Ib clinical trials for Efsubaglutide Alfa from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The drug is being tested for the treatment of obesity in adolescents.The company expects to begin the trial in July and enroll around 36 participants.
HKG:2591
